News from merrimack pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 02, 2012, 08:30 ET

Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers

 Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the presentation of Phase 1 safety and clinical results evaluating two...

Sep 18, 2012, 11:51 ET

Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that research evaluating two novel compounds for advanced cancers, including breast,...

Mar 28, 2012, 23:28 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

 Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines...

Jan 12, 2012, 16:31 ET

Phase 1 Data on MM-398 will be Presented at the ASCO 2012 Gastrointestinal Cancers Symposium

 Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-398, one of its five targeted therapeutic oncology...

Jan 11, 2012, 16:31 ET

Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors

 Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal...

Dec 13, 2011, 16:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers

 Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a...

Nov 30, 2011, 16:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical study combining MM-121, a fully...

Nov 18, 2011, 16:19 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer

   Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of...

Nov 11, 2011, 15:28 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Multiple Programs from Merrimack Pharmaceuticals' Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merrimack Pharmaceuticals, Inc. announced today that they will present seven posters on six novel pipeline programs at the 2011 American...

Oct 11, 2011, 08:46 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully...

Aug 01, 2011, 16:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for the...

Jun 30, 2011, 12:12 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer

Merrimack Pharmaceuticals, Inc. announced today that it will present preclinical data on MM-151, an oligoclonal therapeutic consisting of a...

May 09, 2011, 03:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan

Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. (Taipei, Taiwan) today announced the signing of an agreement under which Merrimack has...

Apr 20, 2011, 09:59 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients

Merrimack Pharmaceuticals, Inc. announced today that five patients have received therapy in a Phase I clinical study combining MM-111 with...

Apr 05, 2011, 11:08 ET

Phase 1 Data on MM-121 Will Be Presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR)

Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-121, one of the five cancer therapeutic agents from the company's novel...

Jan 25, 2011, 03:00 ET
Michael Porter, Ph.D.  (PRNewsFoto/Merrimack Pharmaceuticals, Inc., Stuart Cahill)

Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors

Michael Porter, Ph.D., has joined the board of directors of Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the...

Jan 19, 2011, 07:00 ET

Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium

On February 1, 2011, the Massachusetts Institute of Technology (MIT) Department of Biological Engineering, Center for Biomedical Innovation, and...

Nov 08, 2010, 15:00 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals Awarded $2.44 Million in Grants Under the Patient Protection and Affordable Care Program

Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery...

Sep 13, 2010, 11:22 ET
Merrimack Pharmaceuticals. (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)

Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference

Merrimack Pharmaceuticals today announced that it will present at the Stifel Nicolaus 2010 Healthcare Conference in Boston. William Sullivan, Vice...

Jul 22, 2010, 07:00 ET

Merrimack Pharmaceuticals and sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast Cancer

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2...